Bio Green Med Solution, Inc.

Regulatory Filings • Dec 16, 2014

8-K 1 t1402478_8k.htm FORM 8-K

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2014

CYCLACEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	0-50626	91-1707622
(State or other
jurisdiction	(Commission File
Number)	(IRS Employer
of incorporation)		Identification No.)

200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922 (Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (908) 517-7330

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing

obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 8.01 Other Events.

On December 16, 2014, Cyclacel Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the enrollment of 486 patients, continuation to final analysis and recommendations of the independent Data and Safety Monitoring Board (“ DSMB ”) of the Company’s Phase 3 SEAMLESS study of sapacitabine oral capsules in acute myeloid leukemia (AML). The DSMB determined that the planned futility boundary has been crossed, but saw no reason for patients to discontinue from the study. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and the information contained therein is incorporated herein by reference.

Neither the filing of the press release as an exhibit to this Report nor the inclusion in the press release of a reference to our internet address shall, under any circumstances, be deemed to incorporate the information available at our internet address into this Report. The information available at our internet address is not part of this Report or any other report filed by us with the Securities and Exchange Commission.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press release, dated
December 16, 2014

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| CYCLACEL PHARMACEUTICALS,
INC. | |
| --- | --- |
| By: | /s/
Paul McBarron |
| Name: | Paul McBarron |
| Title: | Executive Vice President—Finance, |
| | Chief Financial Officer and Chief Operating Officer |

Date: December 16, 2014

Field: Page; Sequence: 3

Field: /Page

EXHIBIT INDEX

| Exhibit
No. | Description |
| --- | --- |
| 99.1 | Press release, dated
December 16, 2014. |

Field: Page; Sequence: 4; Options: Last

Field: /Page